Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma.
World J Surg
; 40(8): 1941-50, 2016 Aug.
Article
em En
| MEDLINE
| ID: mdl-27098539
ABSTRACT
BACKGROUND AND OBJECTIVES:
High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence.METHODS:
Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available.RESULTS:
Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).CONCLUSIONS:
Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quimioembolização Terapêutica
/
Óleo Etiodado
/
Carcinoma Hepatocelular
/
Radioisótopos do Iodo
/
Neoplasias Hepáticas
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article